TransCode Therapeutics entered into a financing agreement on April 6 2026 that provides up to $20 million in capital, announced the following day. The deal consists of $6 million in pre‑paid advances and a three‑year Standby Equity Purchase Agreement (SEPA) that allows the company to sell up to $14 million of common stock under specified conditions.
The pre‑paid advances are structured as convertible promissory notes priced at 95 % of face value, carrying a 5 % annual interest rate. A $1 million principal note will be issued concurrently with the company’s 2025 Form 10‑K filing, while an additional $5 million note is subject to shareholder approval, ensuring that the financing is both immediate and scalable.
The primary purpose of the capital raise is to support the Phase 2a trial of the lead candidate TTX‑MC138 and to fund the integration of the recently acquired Polynoma assets. By extending the company’s runway beyond the previously projected Q4 2026, the financing gives TransCode the liquidity needed to manage its high burn rate and maintain momentum in its clinical development program.
Dr. Philippe P. Calais, Chairman and CEO, said the financing “provides TransCode with financial flexibility and ensures that we can maintain operational momentum as we conduct our Phase 2a trial for TTX‑MC138.” CFO Tom Fitzgerald added that the runway extension “should enable the Company to complete the Phase 2a study and subsequently explore a strategic collaboration for the program.”
The SEPA structure introduces a potential dilution risk, as notes may convert into common stock and the company may issue up to $14 million of shares. Nevertheless, the financing is a critical lifeline for a pre‑revenue biotech, offering the necessary capital to advance its pipeline and pursue strategic opportunities such as collaborations or further acquisitions.
The financing addresses TransCode’s cash‑flow constraints and provides a clearer path to achieving its clinical milestones, reinforcing investor confidence in the company’s long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.